Emtricitabine News and Research

RSS
Emtricitabine, also known as Emtriva or FTC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Emtricitabine in capsule form was approved by the FDA on July 2, 2003, for use with other antiretroviral agents in the treatment of HIV infection in adults. Emtricitabine oral solution was approved by the FDA on September 28, 2005, and is now approved for use with other anti-HIV drugs in the treatment of HIV-1 infection in patients older than 3 months of age. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Long-acting injectable CAB-LA safe for HIV PrEP during pregnancy, study finds

Long-acting injectable CAB-LA safe for HIV PrEP during pregnancy, study finds

Vaginal ring and oral PrEP found to be safe for HIV prevention among pregnant cisgender women

Vaginal ring and oral PrEP found to be safe for HIV prevention among pregnant cisgender women

New early phase study evaluates “on-demand” HIV prevention method for women

New early phase study evaluates “on-demand” HIV prevention method for women

Major UK study finds high demand and efficacy for HIV PrEP among sexual health service attendees

Major UK study finds high demand and efficacy for HIV PrEP among sexual health service attendees

Comparing HIV PrEP medications: Study explores hypertension risk in adults on TAF vs. TDF

Comparing HIV PrEP medications: Study explores hypertension risk in adults on TAF vs. TDF

Study reveals substantial gap in PrEP access in more than one-third of New England colleges and universities

Study reveals substantial gap in PrEP access in more than one-third of New England colleges and universities

The decision-making process for the launch of trials for COVID-19 repurposed antivirals

The decision-making process for the launch of trials for COVID-19 repurposed antivirals

Two newer simplified HIV treatment options found to be at least as effective as the standard of care

Two newer simplified HIV treatment options found to be at least as effective as the standard of care

Use of dapivirine vaginal ring during third trimester of pregnancy poses no safety concerns

Use of dapivirine vaginal ring during third trimester of pregnancy poses no safety concerns

Study reports two cases of ocular MPox in HIV-infected patients

Study reports two cases of ocular MPox in HIV-infected patients

Monkeypox infection in a smallpox-vaccinated patient

Monkeypox infection in a smallpox-vaccinated patient

Monkeypox virus infection in an immunocompromised patient

Monkeypox virus infection in an immunocompromised patient

FDA approval of long-acting injectable drug marks a vital expansion of HIV prevention options

FDA approval of long-acting injectable drug marks a vital expansion of HIV prevention options

Study: Adolescent girls and young women can and will use HIV prevention products with consistency

Study: Adolescent girls and young women can and will use HIV prevention products with consistency

Facets of SARS-CoV-2 infection and animal models

Facets of SARS-CoV-2 infection and animal models

PrEP prescription can make a positive difference in women who inject drugs

PrEP prescription can make a positive difference in women who inject drugs

New insight into role of autophagy in controlling SARS-CoV-2 infection

New insight into role of autophagy in controlling SARS-CoV-2 infection

Cabotegravir highly effective in preventing HIV among women

Cabotegravir highly effective in preventing HIV among women

HIV drugs cause immune-system changes that can improve resistance to viral infections

HIV drugs cause immune-system changes that can improve resistance to viral infections

Researchers launch study to evaluate safety of HIV prevention methods in breastfeeding women

Researchers launch study to evaluate safety of HIV prevention methods in breastfeeding women

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.